title: Chronic inflammatory demyelinating polyneuropathy.
abstract: Chronic inflammatory demyelinating polyneuropathy (CIDP) is characterized clinically by a progressive symmetrical weakness evolving over a period of at least 2 months. There is increased CSF protein and conduction block, reduced nerve conduction velocities, increased distal latencies, and/or absent F wave or prolonged F wave latency in two or more nerves. Incidence is lower in children (10 times less) than in adults, and the condition presents in an acute or subacute manner with frequent relapses. It is not associated with other systemic diseases such as neoplasia, diabetes mellitus, or monoclonal gammopathies. It appears to be immune-related as a variety of humoral and cellular autoimmune mechanisms have been implicated. Treatment is based on results obtained in randomized clinical trials (RCTs) conducted in adults as such studies are lacking in the pediatric population. The evolution of CIDP is more favorable in children than in adults, with 80-100% response rates to standard treatments (steroids, intravenous immunoglobulins, and/or plasmapheresis) and excellent outcome with complete functional recovery in most patients. Cases refractory to standard therapies do exist in children, for which azathioprine, methotrexate, and mycophenolate mofetil alone or more often in association with other treatments have been used. However, safety and efficacy data are still insufficient to give specific recommendations regarding the optimal choice.
authors.affiliation: Neurology Service, Department of Pediatrics, Centre Hospitalier Universitaire Sainte-Justine, Université de Montréal, Montréal, Canada. Electronic address: michel.vanasse@umontreal.ca.
authors.forename: Michel
authors.initials: M
authors.lastname: Vanasse
authors.forename: Elsa
authors.initials: E
authors.lastname: Rossignol
authors.forename: Elie
authors.initials: E
authors.lastname: Hadad
mesh_terms: D002648:Child; D006801:Humans; D007111:Immunity, Cellular; D056724:Immunity, Humoral; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D015994:Incidence; D009431:Neural Conduction / Q000502:physiology; D020277:Polyradiculoneuropathy, Chronic Inflammatory Demyelinating / Q000175:diagnosis* / Q000188:drug therapy / Q000453:epidemiology / Q000276:immunology; D011379:Prognosis
chemical_list: D016756:Immunoglobulins, Intravenous